Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

IMPORTANCE: Despite approximately 40% of patients having Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark clinical trials that led to the use of pembrolizumab as standard of care in advanced non–small cell lung cancer (NSCLC) exc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Netw Open
Main Authors: Sehgal, Kartik, Gill, Ritu R., Widick, Page, Bindal, Poorva, McDonald, Danielle C., Shea, Meghan, Rangachari, Deepa, Costa, Daniel B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7879233/
https://ncbi.nlm.nih.gov/pubmed/33570575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.37120
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados